PEGYLATED GRANULOCYTE COLONY STIMULATING FACTOR
Background and Date of Approval
Pegylated granulocyte colony-stimulating factor is the active ingredient in this medication. It is synthesised from the bacterium E. coli. It belongs to a class of proteins called cytokines and mimics the natural protein produced by the body. It is a leucocyte growth factor indicated to reduce infections in patients receiving anti-cancer drugs that suppress bone marrow function. Pegylated granulocyte colony-stimulating factor received approval from the US Food and Drug Administration (FDA) on February 20, 2002, for reducing the incidence of infection as manifested by febrile neutropenia (a decrease in white blood cell count).
Uses
Pegylated granulocyte colony-stimulating factor is used for patients with chemotherapy-induced neutropenia, chemotherapy-induced fever, and chemotherapy-induced infections.
How is it administered?
Peglylated granulocyte colony-stimulating factor is administered as an injection under the skin. The injection should be given in the abdomen (at least 2 inches away from the belly button), the front of the thighs, or the upper arm. It is usually administered once per chemotherapy cycle. The medication should be administered at least 24 hours after the last dose of chemotherapy to allow for proper bone marrow recovery.
Side Effects
The most common side effects of Peglylated granulocyte colony-stimulating factors include bone pain, headache, fatigue, and musculoskeletal pain. Less common side effects include allergic reactions, including anaphylaxis, spleen rupture, acute respiratory distress syndrome (ARDS), and glomerulonephritis.
Warnings
Rare cases of splenic rupture have been reported in patients receiving Peglylated granulocyte colony-stimulating factor. In rare cases, this medication can cause ARDS, a serious lung condition that can cause shortness of breath, coughing, and fatigue. Patients should notify their healthcare provider immediately if they experience any symptoms of ARDS. It can cause allergic reactions in some patients, which can be severe or life-threatening. This medicine should be used cautiously in patients with sickle cell disease, as it can increase the risk of a sickle cell crisis. There have been reports of secondary malignancies, such as leukemia and myelodysplastic syndrome, in patients receiving this medicine.
Precautions
You should be monitored for signs and symptoms of splenic ruptures, such as left upper abdominal pain or shoulder pain while receiving Peglylated granulocyte colony-stimulating factor. You should notify your healthcare provider immediately if these symptoms occur. Patients should tell the healthcare provider immediately if they experience any symptoms of ARDS. you require close monitoring for signs of an allergic reaction, such as rash, itching, or swelling. Patients with sickle cell disease also required close monitoring during treatment.
Word of Advice
Follow your healthcare provider's instructions when taking pegylated granulocyte colony-stimulating factor or any medication. Patients should be monitored for signs of allergic reaction, such as rash, itching, or swelling, and should seek immediate medical attention if these symptoms occur. Discuss any questions or concerns with your healthcare provider. Be aware of potential side effects and notify your healthcare provider if you experience any unusual symptoms. This medication should be used with caution in patients with severe renal impairment. Pregnant and breastfeeding women should discuss potential risks and benefits with a healthcare provider before taking this medication. Maintain a healthy and balanced diet to support overall health and well-being.
References
Amgen Inc., [Revised on Feb 2021] [Accessed on 2 May 2023], https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/neulasta/neulasta_pi_hcp_english.pdf Accord Healthcare Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 2nd May 2023], https://www.medicines.org.uk/emc/files/pil.9531.pdf James L. Zehnder, Agents Used in Cytopenias; Hematopoietic Growth Factors, Langeâs Basic & Clinical Pharmacology, 14th Edition, 2018, 591-607 Maureen S. Phillips, Peglylated granulocyte colony-stimulating factor, Clinical Journal of Oncology Nursing, 2003, 7(2), 238, https://cjon.ons.org/sites/default/files/5205800724MRU571_first.pdf
Frequently Asked Questions
Can I take this medicine if I have asthma?
If you have asthma or any other respiratory condition, it is important to discuss the use of Peglylated granulocyte colony-stimulating factor with your healthcare provider. While there is no specific contraindication for using this medication in patients with asthma, caution should be exercised as the medication may cause respiratory side effects such as shortness of breath or chest tightness.
What is the side effect of the Peglylated granulocyte colony-stimulating factor?
The most common side effects of Pegylated granulocyte colony-stimulating factors include bone pain, headache, fatigue, and musculoskeletal pain. Less common side effects include allergic reactions, including anaphylaxis, spleen rupture, acute respiratory distress syndrome (ARDS), and glomerulonephritis.
How is Peglylated granulocyte colony-stimulating factor different from filgrastim?
Peglylated granulocyte colony-stimulating factor and filgrastim are both medications that stimulate the production of white blood cells. However, it is a longer-acting form of filgrastim so it can be given less frequently.
Can Peglylated granulocyte colony-stimulating factor cause bone pain?
Bone pain is a known side effect of Peglylated granulocyte colony-stimulating factor and may be more common in patients who are receiving chemotherapy. If you experience bone pain while taking it, contact your healthcare provider.
Can Peglylated granulocyte colony-stimulating factor be used to prevent infections in healthy individuals?
Peglylated granulocyte colony-stimulating factor is not approved for use in healthy individuals as a preventive measure against infections. It is only approved for use in patients at risk of developing infections due to their underlying medical condition or treatment.
Can Peglylated granulocyte colony-stimulating factor be used to treat other medical conditions besides cancer?
Peglylated granulocyte colony-stimulating factor is primarily used to support patients undergoing cancer treatment by increasing their white blood cell count and reducing their risk of infections. However, it may also be used in other medical conditions where low white blood cell counts are a concern, such as severe chronic neutropenia.